Eye-openers for advanced management of elderly-onset rheumatoid arthritis
Authors' conclusion
Despite unfavourable prognostic factors at diagnosis, EORA patients have similar outcomes compared with their younger counterparts if a treat-to-target management approach is applied. Notably, fewer EORA patients required bDMARDs to reach the same treatment target.
Study context
- Population
- All RA patients from the tREACH trial, managed treat-to-target with a fixed medication protocol
- Participants
- 119 / 208 / 98
- Comparison
- Elderly-onset RA (EORA) vs MORA vs young-onset RA (YORA)
- YORAn = 119
- MORAn = 208
- EORAn = 98
- Primary endpoint
- Clinical outcomes and patient-reported outcomes (PROs) (pain NRS, fatigue VAS, HAQ-DI, EQ-5D-3L, HADS-D, HADS-A) by age of RA onset
- Follow-up
- 2 years
Methodological detailsmulticentre, stratified, single-blinded, treat-to-target, fixed medication protocol, mixed models
- Multicentre
- Stratified
- Single-blinded
- Treat-to-target
- Fixed medication protocol
- Mixed models
Primary result
As reported in the abstract
- EORA vs YORA
- difference in pain (lower) 1 (95% CI 0.5–1.6)
- EORA vs YORA
- difference in fatigue (lower) 17.3 mm (95% CI 11.3–23.4)
- EORA vs MORA
- difference in pain (lower) 0.6 (95% CI 0.1–1)
- EORA vs MORA
- difference in fatigue (lower) 5.8 mm (95% CI 0.7–10.9)
Further findings
bDMARD usage · 2 years
Baseline characteristics at diagnosis
- EORA had more swollen joints, erosions and comorbidities than younger patients
Original publication
Eye-openers for advanced management of elderly-onset rheumatoid arthritis. Rheumatology (Oxford). Published 9 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →